表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌的效果及安全性  

Clinical efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitor in the treatment of advanced non-small cell lung cancer

作　　者：冯博琳 常静 Feng Bolin;Chang Jing(Department of Respiratory and Critical Care Medicine,Yulin Hospital,the First Affiliated Hospital of Xi’an Jiaotong University,Yulin 719000,China)

机构地区：[1]西安交通大学第一附属医院榆林医院呼吸与危重症医学科,榆林719000

出　　处：《中国实用医刊》2025年第3期82-85,共4页Chinese Journal of Practical Medicine

摘　　要：目的探讨表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗晚期非小细胞肺癌(NSCLC)的效果及安全性。方法回顾性抽取2021年1月至2023年10月西安交通大学第一附属医院榆林医院收治的晚期NSCLC患者82例,按照治疗方案分为对照组(41例,予以常规化疗)和观察组(41例,予以EGFR-TKI治疗+常规化疗)。比较两组疗效、治疗前后肿瘤标志物水平及不良反应发生情况。结果观察组客观缓解率(85.37%,35/41)高于对照组(63.41%,26/41),P<0.05。治疗前,两组血清癌胚抗原、糖类抗原125、神经烯醇化酶水平比较,差异未见统计学意义(P>0.05);治疗后,观察组上述指标水平均低于对照组(P均<0.05)。两组脱发、皮疹、胃肠道反应、神经毒性、骨髓抑制、乏力发生率比较,差异未见统计学意义(P>0.05)。结论将EGFR-TKI应用于晚期NSCLC的治疗,有助于改善临床疗效,调节机体肿瘤标志物水平,且较安全。Objective To investigate the efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)in the treatment of advanced non-small cell lung cancer(NSCLC).MethodsEighty-two patients with advanced NSCLC admitted to Yulin Hospital,the First Affiliated Hospital of Xi’an Jiaotong University from January 2021 to October 2023 were retrospectively selected.And they were divided into the control group(41 cases,treated by conventional chemotherapy)and the observation group(41 cases,treated with EGFR-TKI combined with conventional chemotherapy)according to the treatment plan.The treatment efficacy,the levels of tumor markers before and after treatment,and the occurrence of adverse reactions were compared between the two groups.ResultsThe objective response rate of the observation group(85.37%,35/41)was higher than that of the control group(63.41%,26/41),P<0.05.Before treatment,there was no significant difference in the levels of serum carcinoembryonic antigen,carbohydrate antigen 125 and neuron specific enolase between the two groups(P>0.05);after treatment,the levels of the above indicators in the observation group were lower than those in the control group(all P<0.05).There was no significant difference in the incidences of alopecia,rash,gastrointestinal reactions,neurotoxicity,bone marrow suppression,and fatigue between the two groups(P>0.05).ConclusionsThe application of EGFR-TKI in the treatment of advanced NSCLC is helpful to improve clinical efficacy,and regulate the levels of tumor markers,with better safety.

关 键 词：非小细胞肺癌 表皮生长因子酪氨酸激酶抑制剂 肿瘤标志物 

分 类 号：R734.2[医药卫生—肿瘤]